Ubs Group Ag Oncorus, Inc. Transaction History

Ubs Group Ag

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$0.28 - $0.45 $4,102 - $6,592	14,650 New	14,650 $4,000
Q3 2022 Nov 10, 2022	SELL	$0.85 - $1.65 $3,750 - $7,279	-4,412 Reduced 55.04%	3,604 $3,000
Q2 2022 Aug 10, 2022	BUY	$1.04 - $1.86 $8,336 - $14,909	8,016 New	8,016 $10,000
Q1 2022 May 16, 2022	SELL	$1.44 - $5.62 $4,524 - $17,658	-3,142 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$5.03 - $11.63 $15,804 - $36,541	3,142 New	3,142 $17,000
Q3 2021 Nov 15, 2021	SELL	$9.29 - $14.27 $566,132 - $869,613	-60,940 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$13.3 - $17.3 $777,132 - $1.01 Million	58,431 Added 2328.86%	60,940 $841,000
Q1 2021 May 12, 2021	SELL	$11.89 - $35.55 $56,025 - $167,511	-4,712 Reduced 65.25%	2,509 $35,000
Q4 2020 Feb 11, 2021	BUY	$15.0 - $35.15 $108,315 - $253,818	7,221 New	7,221 $233,000

Ticker ONCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,973,100
Description
Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various canc...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.